Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Observational 8Interventional 1

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 8Gastrointestinal 8Genitourinary 5Myeloid 4Breast 4Dermatologic 3Sarcoma 2Plasma cell 2Other solid neoplasm 2Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Classical hematology 1CNS 1

Conditions

Optic Nerve Glioma 1Medulloblastoma 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Amplified Fragment Length Polymorphism Analysis × CNS × Clear all
NCT00360854 2013-09-20

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

National Cancer Institute (NCI)

Phase 1 Unknown
48 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡